Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Corporate Update (November 2026)
17 slides from Satellos Bioscience's corporate update, Nov 6, 2026

Slide 1: BASECAMP Clinical and Regulatory Update
BASECAMP Clinical and Regulatory Update NOVEMBER 6 · INVESTOR CALL REGENERATING MUSCLE FROM WITHIN

Slide 2: Agenda
© 2026 Satellos Bioscience T O D AY ' S C A L L Agenda Caitlin Lowie 1 Welcome Vice President of Investor Relations & Communications Frank Gleeson 2 Opening remarks Co-founder & CEO Wildon Farwell, MD 3 Clinical & regulatory update Chief Medical Officer Frank Gleeson 4 Closing remarks Co-founder & C

Slide 3: Legal Disclaimers
© 2026 Satellos Bioscience Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable United States securities laws and “forward-looking information” under applicable Canadian securities laws (collectively, “forward- looking statements”). Any statemen

Slide 4: Agenda
© 2026 Satellos Bioscience T O D AY ' S C A L L Agenda Caitlin Lowie 1 Welcome Vice President of Investor Relations & Communications Frank Gleeson 2 Opening remarks Co-founder & CEO Wildon Farwell, MD 3 Clinical & regulatory update Chief Medical Officer Frank Gleeson 4 Closing remarks Co-founder & C

Slide 5: Strategic Overview and Mission
© 2026 Satellos Bioscience STRATEGIC OVERVIEW Strategic Overview and Mission OUR MISSION To improve the lives of people living with devastating muscle diseases by restoring the body’s natural ability to regenerate muscle. Grounded in science. Inspired by need. REGENERATING MUSCLE FROM WITHIN 5

Slide 6: Agenda
© 2026 Satellos Bioscience T O D AY ' S C A L L Agenda Caitlin Lowie 1 Welcome Vice President of Investor Relations & Communications Frank Gleeson 2 Opening remarks Co-founder & CEO Wildon Farwell, MD 3 Clinical & regulatory update Chief Medical Officer Frank Gleeson 4 Closing remarks Co-founder & C

Slide 7: BASECAMP Endpoint Refinement and Regulatory Strategy
© 2026 Satellos Bioscience Q4 2026 REGULATORY UPDATE BASECAMP Endpoint Refinement and Regulatory Strategy Following recent FDA interactions, BASECAMP’s primary efficacy endpoint is change in vastus lateralis fat fraction measured by MRI W H AT C H A N G E D FDA W H AT I T M E A N S Potential acceler

Slide 8: A Clinical Measure Aligned with Forazapadin's Novel Mechanism
© 2026 Satellos Bioscience WHY FAT FRACTION A Clinical Measure Aligned with Forazapadin’s Novel Mechanism Objective measure with the potential to reflect DMD pathophysiology and forazapadin’s expected biological effect Fat fraction increases with age, including at BASECAMP ages 1 Fat Fraction consis

Slide 9: Increasing Fat Fraction Is Associated with Functional Decline
© 2026 Satellos Bioscience WHY FAT FRACTION Increasing Fat Fraction Is Associated with Functional Decline As vastus lateralis fat fraction increases, boys with DMD lose function, and a faster increase is associated with earlier loss of ambulation. As fat fraction increases, function is lost Faster i

Slide 10: TRAILHEAD Showed Decrease in Biceps Brachii Fat Fraction at 5 Months
© 2026 Satellos Bioscience MUSCLE COMPOSITION TRAILHEAD Showed Decrease in Biceps Brachii Fat Fraction at 5 Months Individual Values and Changes Mean Change Natural History of Elbow Flexor Fat-Fraction1 Dixon (%) CL-101 and TRAILHEAD ages Biceps Brachii MRI Fat Fraction (%) 0 Baseline Month 5 Change

Slide 11: Rationale for Assessing Muscle Composition at 12 Weeks
© 2026 Satellos Bioscience WHAT SUPPORTS A 12-WEEK READOUT Rationale for Assessing Muscle Composition at 12 Weeks Biology, preclinical work and early human data support a measurable signal within the controlled period. Muscle regeneration can begin within about one month Natural history: fat fractio

Slide 12: MRI Fat Fraction May Support Potential Accelerated Approval Pathway
© 2026 Satellos Bioscience REGULATORY STRATEGY MRI Fat Fraction May Support Potential Accelerated Approval Pathway Type C interaction Totality of the evidence Treatment objective FDA interactions informed the MRI fat fraction alongside clinical Evaluate stabilization or reduction in clinical a

Slide 13: BASECAMP Protocol, Readout and Longer-Term Follow-up
© 2026 Satellos Bioscience BASECAMP · Q1 2027 READOUT BASECAMP Protocol, Readout and Longer-Term Follow-up Global, randomized, double-blind, placebo-controlled Phase 2 study in 53 ambulatory boys aged 7, 8 and 9. 53 boys 12 weeks · forazapadin (2 doses) vs. placebo 36 weeks · all on forazapadin 17 s

Slide 14: Agenda
© 2026 Satellos Bioscience T O D AY ' S C A L L Agenda Caitlin Lowie 1 Welcome Vice President of Investor Relations & Communications Frank Gleeson 2 Opening remarks Co-founder & CEO Wildon Farwell, MD 3 Clinical & regulatory update Chief Medical Officer Frank Gleeson 4 Closing remarks Co-founder & C

Slide 15: Key Takeaways and Upcoming Milestones
© 2026 Satellos Bioscience CLOSING REMARKS Key Takeaways and Upcoming Milestones An objective primary efficacy endpoint, a defined readout and continued regulatory engagement. Key takeaways Upcoming anticipated milestones MRI fat fraction is now BASECAMP’s primary efficacy TRAILHEAD 12-month data (f

Slide 16: Thank You Q&A
© 2026 Satellos Bioscience THANK YOU Q&A ir@satellos.com · TSX: MSCL · NASDAQ: MSLE REGENERATING MUSCLE FROM WITHIN 16

Slide 17: Reimagine Regenerate Realize
© 2026 Satellos Bioscience THANK YOU Reimagine how muscle diseases are treated Regenerate muscle with an oral, once-daily medicine Realize a new future for patients and families REGENERATING MUSCLE FROM WITHIN 17
Source: company website
More decks from Satellos Bioscience Inc
Corporate Update (July 2026)14 slides · Jul 8, 2026
2026 Bloom Burton & Co. Healthcare Investor Conference23 slides · April 2026
Technical Presentation (February 2026)52 slides · Feb 24, 2026
Investor Presentation (February 2026)21 slides · February 2026
Investor Presentation (October 2025)19 slides · October 2025
Investor Presentation (June 2025)22 slides · Jun 5, 2025